AKBA - Akebia Therapeutics, Inc.
| Previous Close | 4.4300 |
| Open | 4.4500 |
| Bid | 0.0000 x 800 |
| Ask | 6.7000 x 900 |
| Day's Range | 4.4000 - 4.6200 |
| 52 Week Range | 4.0900 - 11.6000 |
| Volume | 1,266,650 |
| Avg. Volume | 1,152,985 |
| Market Cap | 538.634M |
| Beta (3Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5630 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.33 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of AKBA earnings conference call or presentation 9-May-19 1:00pm GMT
Q1 2019 Akebia Therapeutics Inc Earnings Call
- Business Wire•8 days ago
Akebia Therapeutics Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
- Business Wire•15 days ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebia’s common stock on May 31, 2019, including an option to purchase 250,000 shares granted to Dell Faulkingham, Akebia’s newly-hired Senior Vice President, Chief Commercial Officer. The options were granted as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $4.45 per share, which is equal to the closing price of Akebia’s common stock on the grant date.
- Business Wire•21 days ago
Akebia Therapeutics to Participate in Upcoming Investor Conferences
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Motley Fool•last monthAkebia Therapeutics, Inc. (AKBA) Q1 2019 Earnings Call Transcript
AKBA earnings call for the period ending March 31, 2019.
- Insider Monkey•last month
Here’s What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
- Associated Press•last month
Akebia Therapeutics: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 62 cents per share. Losses, adjusted for one-time gains and costs, were 44 cents per share. The results fell short of Wall Street expectations. ...
- Business Wire•last month
Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments
CAMBRIDGE, Mass.-- -- Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3 INNO 2 VATE Studies; and Additions to Executive Leadership Team to Support Commercial and Clinical Operations. Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney ...
GuruFocus.com•last monthSeth Klarman Keeps Buying This Biotech Stock
Akebia Therapeutics (AKBA) was a top stock pick by Seth Klarman (Trades, Portfolio) last quarter. Warning! GuruFocus has detected 4 Warning Signs with AKBA. Last June, Akebia agreed to combine with Keryx Biopharmaceuticals (KERX), of which Klarman was a major shareholder, controlling more than 20% of the fully diluted stock.
- Zacks•2 months ago
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should Know
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
Akebia and Otsuka Pharmaceutical Development & Commercialization Inc (OPDC) Announce Presentation of Four Posters at the NKF 2019 Spring Clinical Meetings
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, and its strategic development collaborator Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC), announced today that four posters highlighting the unmet clinical need and economic burden among patients with anemia due to chronic kidney disease will be presented at the 2019 Spring Clinical Meetings of the National Kidney Foundation (NKF), to be held May 8 through May 12, 2019 at the Hynes Convention Center in Boston, MA.
- Business Wire•2 months ago
Akebia Therapeutics to Report First Quarter 2019 Financial Results
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2019, on Thursday, May 9, 2019, before the opening of the financial markets. Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, May 9, 2019 to discuss its first quarter financial results. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 4271217.
- Zacks•2 months ago
Akebia Expands Vadadustat Licensing Deal With Vifor Pharma
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
- Business Wire•2 months ago
Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
The Vifor Pharma Group (SIX:VIFN) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.
- Business Wire•2 months ago
Vifor Pharma and Akebia Therapeutics Announce Expansion of License Agreement
The Vifor Pharma Group (VIFN.VX) and Akebia Therapeutics, Inc. (AKBA) today announced that the companies have amended the terms of their license agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a license to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval.
- Business Wire•2 months ago
Akebia Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 11:20 a.m. Eastern Time in New York. A live webcast of the presentation will be available on the company’s website at www.akebia.com. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease.
- CNW Group•3 months ago
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
PETACH TIKVA, Israel , April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (GUD.TO) ("Knight" or the "Company"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the "Nominees") for election to Knight's Board of Directors (the "Board") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison.
- GlobeNewswire•3 months ago
Consolidated Research: 2019 Summary Expectations for ADT, HudBay Minerals, Whirlpool, Akebia Therapeutics, Nevro, and MicroStrategy — Fundamental Analysis, Key Performance Indications
NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•3 months ago
Akebia Therapeutics Inc (AKBA) Files 10-K for the Fiscal Year Ended on December 31, 2018
Akebia Therapeutics Inc is a biopharmaceutical company. Akebia Therapeutics Inc had annual average EBITDA growth of 19.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with AKBA.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT
Q4 2018 Akebia Therapeutics Inc Earnings Call
- Motley Fool•3 months ago
Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript
AKBA earnings call for the period ending December 31, 2018.
- Business Wire•3 months ago
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “We successfully executed a number of strategic initiatives to advance our mission, and with the recent completion of our merger with Keryx, we have emerged as a leading, fully-integrated renal company with the potential to greatly improve care for patients with kidney disease. Mr. Butler continued, “With respect to vadadustat, our lead product candidate, we believe that it has the potential to set a new standard of care for patients with anemia due to chronic kidney disease with a differentiated clinical profile.
